1696 related articles for article (PubMed ID: 31769791)
21. Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges.
Pei WD; Zhang Y; Yin TL; Yu Y
Brief Funct Genomics; 2020 May; 19(3):215-228. PubMed ID: 31819946
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic applications of CRISPR RNA-guided genome editing.
Koo T; Kim JS
Brief Funct Genomics; 2017 Jan; 16(1):38-45. PubMed ID: 27562951
[TBL] [Abstract][Full Text] [Related]
23. Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review).
Alagoz M; Kherad N
Int J Mol Med; 2020 Aug; 46(2):521-534. PubMed ID: 32467995
[TBL] [Abstract][Full Text] [Related]
24. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery.
Ahmad G; Amiji M
Drug Discov Today; 2018 Mar; 23(3):519-533. PubMed ID: 29326075
[TBL] [Abstract][Full Text] [Related]
25. CRISPR/Cas based gene editing: marking a new era in medical science.
Prasad K; George A; Ravi NS; Mohankumar KM
Mol Biol Rep; 2021 May; 48(5):4879-4895. PubMed ID: 34143395
[TBL] [Abstract][Full Text] [Related]
26. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
27. The Smart Programmable CRISPR Technology: A Next Generation Genome Editing Tool for Investigators.
Chakraborty C; Teoh SL; Das S
Curr Drug Targets; 2017; 18(14):1653-1663. PubMed ID: 27231109
[TBL] [Abstract][Full Text] [Related]
28. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in CRISPR/Cas9 mediated genome editing in Bacillus subtilis.
Hong KQ; Liu DY; Chen T; Wang ZW
World J Microbiol Biotechnol; 2018 Sep; 34(10):153. PubMed ID: 30269229
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
Jensen TI; Axelgaard E; Bak RO
Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
[TBL] [Abstract][Full Text] [Related]
31. [Research progress of CRISPR-Cas9 system for gene therapy].
Zhan C; Xia X
Sheng Wu Gong Cheng Xue Bao; 2016 Jul; 32(7):861-869. PubMed ID: 29019208
[TBL] [Abstract][Full Text] [Related]
32. Analysis of microsatellite instability in CRISPR/Cas9 editing mice.
Huo X; Du Y; Lu J; Guo M; Li Z; Zhang S; Li X; Chen Z; Du X
Mutat Res; 2017 Mar; 797-799():1-6. PubMed ID: 28284774
[TBL] [Abstract][Full Text] [Related]
33. CRISPR-Cas9 system: A new-fangled dawn in gene editing.
Gupta D; Bhattacharjee O; Mandal D; Sen MK; Dey D; Dasgupta A; Kazi TA; Gupta R; Sinharoy S; Acharya K; Chattopadhyay D; Ravichandiran V; Roy S; Ghosh D
Life Sci; 2019 Sep; 232():116636. PubMed ID: 31295471
[TBL] [Abstract][Full Text] [Related]
34. Evolution of CRISPR/Cas Systems for Precise Genome Editing.
Hryhorowicz M; Lipiński D; Zeyland J
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762535
[TBL] [Abstract][Full Text] [Related]
35. Recent Advances in Therapeutic Genome Editing in China.
Yang Y; Wang Q; Li Q; Men K; He Z; Deng H; Ji W; Wei Y
Hum Gene Ther; 2018 Feb; 29(2):136-145. PubMed ID: 29446996
[TBL] [Abstract][Full Text] [Related]
36. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
Xu R; Wei P; Yang J
Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
[TBL] [Abstract][Full Text] [Related]
37. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
38. CRISPR/Cas9 for genome editing: progress, implications and challenges.
Zhang F; Wen Y; Guo X
Hum Mol Genet; 2014 Sep; 23(R1):R40-6. PubMed ID: 24651067
[TBL] [Abstract][Full Text] [Related]
39. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
40. CRISPR-Cas9 therapies in experimental mouse models of cancer.
Estêvão D; Rios Costa N; da Costa RG; Medeiros R
Future Oncol; 2018 Aug; 14(20):2083-2095. PubMed ID: 30027767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
